

# Joaquin Mateo

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/160769/joaquin-mateo-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84  
papers

8,876  
citations

36  
h-index

94  
g-index

96  
ext. papers

12,008  
ext. citations

11.7  
avg, IF

5.47  
L-index

#	Paper	IF	Citations
84	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , <b>2015</b> , 161, 1215-1228	56.2	1765
83	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1697-708	59.2	1345
82	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 443-53	59.2	791
81	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 2091-2102	59.2	550
80	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 11428-11436	11.5	383
79	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 162-174	21.7	244
78	Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. <i>Journal of Pathology</i> , <b>2013</b> , 229, 422-9	9.4	235
77	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1006-1017	24.4	232
76	A decade of clinical development of PARP inhibitors in perspective. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1437-1443	14.3	218
75	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , <b>2018</b> , 29, 1895-1902	10.3	181
74	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4586-96	12.9	154
73	PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. <i>European Urology</i> , <b>2015</b> , 67, 795-802	10.2	143
72	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2345-2357	59.2	143
71	Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. <i>Annals of Oncology</i> , <b>2015</b> , 26, 750-755	10.3	139
70	DNA Repair in Prostate Cancer: Biology and Clinical Implications. <i>European Urology</i> , <b>2017</b> , 71, 417-425	10.2	132
69	Sequencing of agents in castration-resistant prostate cancer. <i>Lancet Oncology</i> , <b>2015</b> , 16, e279-92	21.7	123
68	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 985-992	10.2	92

67	Genomics of lethal prostate cancer at diagnosis and castration resistance. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 1743-1751	15.9	85
66	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 4441-4453	15.9	84
65	Managing Nonmetastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 75, 285-293	10.2	83
64	An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib. <i>Targeted Oncology</i> , <b>2016</b> , 11, 401-15	5	81
63	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5585-5593	12.9	74
62	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5981-5992	12.9	73
61	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , <b>2018</b> , 73, 687-693	10.2	70
60	Appraising iniparib, the PARP inhibitor that never was--what must we learn?. <i>Nature Reviews Clinical Oncology</i> , <b>2013</b> , 10, 688-96	19.4	66
59	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. <i>Radiology</i> , <b>2017</b> , 283, 168-177	20.5	57
58	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , <b>2015</b> , 12, 37-47	5.5	49
57	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. <i>European Urology</i> , <b>2019</b> , 75, 184-192	10.2	49
56	Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 724-731	10.2	47
55	Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2017</b> , 120, E30-E44	5.6	47
54	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 2248-53	8.7	45
53	BRCA2 and Other DDR Genes in Prostate Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	43
52	Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1554-1560	10.3	42
51	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 76, 676-685	10.2	41
50	The promise of circulating tumor cell analysis in cancer management. <i>Genome Biology</i> , <b>2014</b> , 15, 448	18.3	38

49	Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. <i>Radiology</i> , <b>2016</b> , 280, 151-60	20.5	36
48	Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 828-36	8.7	33
47	A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 889-96	8.7	32
46	A first-in-human study of the anti- $\alpha_5\beta_1$ integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 1039-46	3.5	27
45	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 687-697	12.9	26
44	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features. <i>Investigative Radiology</i> , <b>2018</b> , 53, 96-102	10.1	24
43	Novel drugs targeting the androgen receptor pathway in prostate cancer. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 567-79	9.6	24
42	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , <b>2021</b> , 79, 200-211	10.2	24
41	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6070-6077	12.9	22
40	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 280-284	3.8	22
39	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 485-493	3.3	21
38	A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2015</b> , 4, 277-85	4.5	20
37	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. <i>Annals of Oncology</i> , <b>2017</b> , 28, 90-95	10.3	19
36	External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone. <i>European Urology</i> , <b>2014</b> , 66, 8-11	10.2	19
35	Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2016</b> , 22, 353-356	2.2	19
34	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , <b>2020</b> , 1, 1041-1053	15.4	18
33	Characterizing CDK12-Mutated Prostate Cancers. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 566-574	12.9	17
32	Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e801-e807	3.3	15

31	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2812-2827	24.4	15
30	Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. <i>European Urology Oncology</i> , <b>2018</b> , 1, 71-77	6.7	14
29	Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2014</b> , e197-203	7.1	14
28	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , <b>2021</b> , 299, 109-119	20.5	14
27	Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. <i>Current Oncology Reports</i> , <b>2019</b> , 21, 42	6.3	13
26	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 79, 762-771	10.2	13
25	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. <i>European Urology Focus</i> , <b>2018</b> , 4, 235-244	5.1	12
24	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4777-4784	12.9	10
23	Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss of Heterozygosity Score. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	9
22	The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 86, 102000	14.4	8
21	PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS5091-TPS5091	2.2	8
20	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. <i>European Urology</i> , <b>2021</b> , 79, 519-529	10.2	8
19	Delivering precision oncology to patients with cancer.. <i>Nature Medicine</i> , <b>2022</b> , 28, 658-665	50.5	7
18	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. <i>Journal of Pathology: Clinical Research</i> , <b>2021</b> , 7, 311-325	5.3	6
17	Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5014-5014	2.2	5
16	Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 195-195	2.2	5
15	Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. <i>Molecular Diagnosis and Therapy</i> , <b>2012</b> , 16, 151-61	4.5	5
14	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 74-83	7.5	5

13	Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1210, 279-300	3.6	4
12	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.. <i>Cancer Research</i> , <b>2022</b> , 82, 1646-1657	10.1	4
11	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 135-135	2.2	3
10	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. <i>Oncotarget</i> , <b>2017</b> , 8, 104430-104443	3.3	3
9	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 81, 37-37	10.2	3
8	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
7	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. <i>European Urology</i> , <b>2021</b> , 80, 243-253	10.2	3
6	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 35, e577-83	7.1	1
5	Biomarkers for Metastatic Castration-resistant Prostate Cancer (mCRPC): Yes or No? Predictive and Response Biomarkers Towards Precision Medicine in mCRPC. <i>European Urology Focus</i> , <b>2016</b> , 2, 465-466	5.1	1
4	Clinical implications of homologous recombination repair mutations in prostate cancer. <i>Prostate</i> , <b>2022</b> , 82,	4.2	1
3	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , <b>2021</b> , 79, 736-746	10.2	0
2	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5071-5071	2.2	
1	PARP Inhibitors. <i>Current Clinical Urology</i> , <b>2014</b> , 253-264		